Recent Stories
American Biotech — The Future Can’t Be Won Without It.RSI is AI Building AI. What DC needs to know about it. Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: Robots

The Wave

Senatein sessionHousein session
Refreshed just now
News

STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming

Why it’s here: FDA rejection of a cell therapy for Duchenne under regulatory review falls within biotechnology's FDA regulation of novel therapies (cell and gene therapy), a live federal regulatory decision with policy dimensions.

Trace across the board

Item

Connected

20 links

About

  • Food and Drug Administration

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming — The Wave